Globus Medical (GMED) Q3 2026 earnings review
Globus Medical cuts its sales plan, but profit margins rise
Globus Medical, a maker of spinal implants and surgical robots, kept expanding its profit margins even as top-line sales stalled. Third-quarter revenue dipped 1% to $764 million because a 26% drop at its Nevro pain-device unit outweighed 3% growth in the rest of the business. Chief executive Keith Pfeil cut the full-year sales plan by $110 million, which by our math leaves fourth-quarter revenue falling 6%, yet held the full-year profit target steady.
| Base business sales (excluding Nevro) | $690.0M +3.0% from a year ago (total sales -0.7%) |
|---|---|
| Profit per share, excluding one-offs | $1.23 +4.4% from a year ago |
| Gross margin, excluding one-offs | 69.5% +1.4 percentage points from a year ago |
| Full-year 2026 revenue outlook | Cut $110M to $3.09B (+5.1% growth); profit outlook held |
⚖️ Verdict: 🔴 Bearish
The story got worse because the company's main growth engine, US Spine, slowed to 2% growth after running between 7% and 10% for four quarters. That forced management to slash its sales plan, proving last quarter's cautious second-half outlook reflected real execution delays rather than conservative planning. The bright spot: in-house factory savings lifted gross margin excluding one-offs for an eighth straight quarter to nearly 70%, while robot placements jumped 73%.
The question now is whether the US Spine slowdown is a brief product delay or the end of easy market-share gains from hiring rival sales reps. Either the delayed launches of custom 3D-printed cages and new patient positioners restore mid-single-digit spine growth in 2027, or core implant growth settles near the 3% market average. First-quarter 2027 US Spine sales and the 2027 outlook will settle it.
🐂 Bull Case
Factory Savings Lifted Gross Margin for an Eighth Quarter
Globus Medical has spent two years bringing manufacturing in-house and cutting supplier costs after buying NuVasive and Nevro. Finance chief Kyle Kline said the third quarter delivered the "eighth straight quarter of sequential adjusted gross profit margin expansion and record quarterly operating cash flow and free cash flow generation".
Gross margin excluding one-offs rose 1.4 percentage points from a year ago to 69.5%. On the standard income statement, the cost of making products (excluding intangible write-downs) fell by 2.3 percentage points of sales to 30.5%. Selling, general and administrative overhead also dropped by 3.0 percentage points of sales to 37.8% because one-time legal charges fell from $28.3 million a year ago to $3.7 million.
These factory savings matter because they protected full-year profit even as sales fell short. What to watch: fourth-quarter gross margin excluding one-offs against the 69% to 70% full-year plan. A reading at or above 70% would show that in-house manufacturing savings still outweigh higher shipping costs.
Robot Sales Rebounded 24% and FDA Closed Its Warning Letter
Enabling Technologies, the unit that sells ExcelsiusGPS surgical robots and Excelsius Hub navigation systems, had shrunk in the second quarter as hospitals shifted from upfront purchases to leases. This quarter, chief executive Keith Pfeil said the unit grew 24% while "deploying 73% more robot and navigation units as compared to the prior year quarter". Across all capital equipment, total units placed rose 45% from a year ago.
Upfront robot purchases and service contracts drove sales to $34.9 million, up 34% from the second quarter. In addition, the US Food and Drug Administration closed its July 2024 warning letter regarding administrative complaint tracking for the ExcelsiusGPS robot. However, Kline warned that fourth-quarter equipment revenue will still face pressure against last year's record $55.6 million quarter as more hospitals choose leases over cash purchases.
What to watch: fourth-quarter Enabling Technologies revenue and unit placement growth. Another quarter of rising unit placements alongside lower upfront revenue would confirm that hospitals are signing multi-year leases rather than delaying robot installations.
Record Free Cash Flow Funded a $500 Million Buyback Boost
Globus generated a record $224.8 million in free cash flow during the third quarter, up 5.1% from a year ago even though spending on property and equipment rose 12.8% to $40.4 million. Over the first nine months of 2026, free cash flow reached $564.2 million, up 46.0% from the same period last year.
The medical device maker spent $142.9 million to buy back 1.9 million shares in the quarter, bringing nine-month repurchases to $279.0 million, or nearly half of its free cash flow. With $110 million left on its 2025 buyback plan, the board approved "a $500 million increase to our existing share repurchase program", Kline said.
What to watch: fourth-quarter share repurchases and diluted share count. Continued buying at the third-quarter pace would shrink the share count further and lift profit per share in 2027.
Trauma and Neuromonitoring Kept Growing Double Digits
Outside of spine and pain devices, Globus sells orthopedic plates, screws and nails for broken bones (Trauma) and nerve-monitoring services for the operating room (Neuromonitoring). Both units delivered double-digit percentage sales growth for a fifth consecutive quarter, with Trauma sales rising 19% from a year ago.
Pfeil said hospitals previously viewed the business as a spine maker dabbling in trauma, but the company is now winning full surgeon teams at major Level 1 and Level 2 trauma centers. Because Pfeil views the current trauma product bag as full, the unit can keep growing without needing acquisitions.
What to watch: whether management breaks out exact dollar sales for Trauma in the annual report. A separate disclosure would show how much of the core implant business now rests on trauma centers rather than spine surgeons.
🐻 Bear Case
US Spine Growth Slowed to 2% on Product Delays and Recruiting
US Spine is the company's main profit engine, and management had argued for two quarters that its full-year sales target was merely cautious. Instead, US Spine growth slowed to 1.8% from a year ago, down from 7.3% in the second quarter and 10.0% in the first. Pfeil blamed "timing delays around new product launches and lower contributions from competitive recruiting".
"I think there's things that we could have done better to achieve the growth that we thought we were going to get," Pfeil said. Lingering production issues delayed the rollout of SCRIPT (3D-printed custom spinal cages and rods) and the XLIF Prone positioner and retractor, pushing their sales contribution into 2027. Meanwhile, sales reps hired from rivals brought over less business than last year's recruits.
Because of the slowdown, Globus cut its 2026 sales outlook by $110 million at the middle of the range to $3.09 billion. What to watch: first-quarter 2027 US Spine growth once SCRIPT and XLIF Prone are in full use. A rebound above 5% would show the slowdown was a product timing delay rather than lost market share.
Nevro Sales Kept Shrinking as Patient Trials Lagged
Globus bought Nevro, a maker of spinal cord stimulators that treat chronic pain, in 2025 and cut its staff to make it profitable. Last quarter, executives expected patient trial volumes — the temporary implants patients test before getting a permanent device — to recover by the end of 2026.
- Nevro third-quarter sales: $73.7 million, down 25.7% from a year ago and down 9% from the second quarter
- Nevro Ebitda margin excluding one-offs: 19.9% in the third quarter and 17.9% year-to-date, up more than 10 percentage points from 2025
- New product timeline: HFX Elite implant generator scheduled for a first-half 2027 commercial launch
Kline admitted that "the recovery from lost sales volume has been delayed beyond our previous expectations". Although Globus has finished rehiring lost sales reps, those new reps are still in training and have not yet lifted patient trial volumes.
What to watch: fourth-quarter Nevro sales against the third quarter's $73.7 million level. A sequential rise would show that the newly trained sales force has stopped the revenue slide ahead of the HFX Elite launch.
Risks This Quarter Didn't Answer
Several standing concerns either worsened slightly or received no concrete numbers in the third-quarter materials.
- International spine slowdown: total international sales fell 5.7%, and sales excluding Nevro dropped from 14.5% growth in the first half to roughly flat as one-time backlog orders faded and Japan stayed weak.
- Mid-70s gross margin timeline: Kline reiterated the long-term goal of returning gross margin excluding one-offs to the mid-70% range, but did not clarify whether that happens in 2027 or later.
- Rising bad-debt reserves: the balance-sheet allowance for expected credit losses rose to $47.9 million, up 43% from $33.4 million at the end of 2025, with no explanation on the call.
- Delayed research spending: management lowered 2026 research and development spending to 4.5%–5.0% of sales (from 5.0%–6.0%), pushing the planned cost step-up into 2027.
- Robot lease economics: management gave percentage growth for robot placements (+73% for EGPS/eHub, +45% total capital units) but still does not disclose exact unit counts or the split between leases and cash sales.
👓 Other Themes
Two Small Deals Expand Cranial Surgery and AI Software
Globus closed two small acquisitions during the quarter, spending $22.4 million in cash across the first nine months of 2026. It bought Synaptive Medical's assets out of Canadian receivership to enter the cranial neurosurgery market (estimated at 2 million procedures a year) and acquired Higgs Boson to add patient-tracking software before and after surgery. Pfeil said neither deal will add meaningful revenue in 2026 or 2027.
💲 Other KPIs
Inventories rose 8.5% from $759.3 million at the end of 2025 and increased sequentially from $810.9 million in the second quarter, even as third-quarter revenue dipped 0.7%. Higher inventory tied up $60.1 million of operating cash flow over the first nine months of 2026, compared with $17.4 million a year ago.
Total cash and marketable securities rose 38.5% from $629.1 million at the end of 2025, up from $799.3 million in the first quarter and $840.5 million in the second. Globus carries no bank debt or senior notes after paying off $450 million of convertible debt in 2025, lifting third-quarter net interest income to $8.4 million.
Weighted average diluted shares fell from 138.2 million in the first quarter of 2026 to 136.0 million in the third quarter as the orthopedic group bought back 3.5 million shares over the first nine months. Compared with a year ago, diluted shares rose 0.5% (from 135.4 million) due to employee stock option exercises.
🔮 Guidance
Cut. Management lowered the full-year sales plan by $110 million at the middle of the range, pointing to 5.1% growth for the year. By our math, that leaves $776.8 million for the fourth quarter, a 6.0% drop from a year ago and down from this quarter's 0.7% dip. Delayed spine product launches, slower Nevro recovery, and tough fourth-quarter robot comparisons drove the reduction.
Unchanged. The plan still calls for full-year profit per share excluding one-offs to grow 24.4% to 26.9%. By our math, the middle of the range leaves $1.31 for the fourth quarter, up 2.3% from a year ago compared with 4.4% growth in the third quarter. Globus had raised this target three times in a row (+$0.10, +$0.30, +$0.25) before holding it steady this quarter.
Unchanged. The surgical device company still expects full-year gross margin excluding one-offs to land between 69% and 70%, an improvement of 0.9 to 1.9 percentage points over 2025. With nine-month gross margin already at 69.4% and the third quarter at 69.5%, the business is tracking in the middle of the full-year range.
Cut. Kline lowered expected full-year research and development spending by half a percentage point at the bottom of the range and a full point at the top. Research spending was 4.5% of sales in the third quarter and 4.6% over the first nine months, as cost cuts from recent mergers and hiring delays pushed planned engineering investments into 2027.
❓ Key Questions
Why did bad-debt reserves jump 43% this year?
The balance-sheet allowance for expected credit losses rose from $33.4 million at the end of 2025 to $47.9 million in the third quarter, while accounts receivable stayed flat at $675.3 million. Management has not explained which customers or regions are struggling to pay.
How many robots were placed, and under what terms?
Executives reported that ExcelsiusGPS and eHub unit deployments rose 73% while total capital units rose 45%. Without the exact unit count or the split between upfront cash sales and multi-year leases, investors cannot model future implant pull-through.
What is the exact timeline for mid-70% gross margins?
Gross margin excluding one-offs has risen only 0.1 to 0.2 percentage points per quarter this year, reaching 69.5%. At that pace, reaching the promised mid-70% range would take several years unless new factory savings accelerate in 2027.
How much will research spending rise in 2027?
Lowering the 2026 research and development plan to 4.5%–5.0% of sales helped protect this year's profit per share despite the $110 million sales cut. Management warned that engineering headcount and spending will step up over the next several quarters, which could limit 2027 margin gains.